Clinical Trial Update: Brightline-4: A Study to Test How Well Brigimadlin is Tolerated by People With a Type of Cancer Called Dedifferentiated Liposarcoma [Phase 3]

View source ↗

Summary

Phase 3 Brightline-4 trial evaluating brigimadlin tolerability in patients with dedifferentiated liposarcoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dedifferentiated Liposarcoma
• Liposarcoma

Drugs mentioned

• brigimadlin (brigimadlin)

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Liposarcoma, Dedifferentiated | Phase 3 | Status: COMPLETED